364 related articles for article (PubMed ID: 29703642)
21. The effects of Lycii Radicis Cortex on RANKL-induced osteoclast differentiation and activation in RAW 264.7 cells.
Kim JH; Kim EY; Lee B; Min JH; Song DU; Lim JM; Eom JW; Yeom M; Jung HS; Sohn Y
Int J Mol Med; 2016 Mar; 37(3):649-58. PubMed ID: 26848104
[TBL] [Abstract][Full Text] [Related]
22. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.
Han B; Geng H; Liu L; Wu Z; Wang Y
Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573
[TBL] [Abstract][Full Text] [Related]
23. Monotropein Protects against Inflammatory Bone Loss and Suppresses Osteoclast Formation and Bone Resorption by Inhibiting NFATc1 via NF-κB and Akt/GSK-3β Pathway.
Zhang Q; Hu S; He Y; Song Z; Shen Y; Zhao Z; Zhang Q; Qin L; Zhang Q
Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235631
[TBL] [Abstract][Full Text] [Related]
24. Anti-Osteoporotic Effects of Polysaccharides Isolated from Persimmon Leaves via Osteoclastogenesis Inhibition.
Hwang YH; Ha H; Kim R; Cho CW; Song YR; Hong HD; Kim T
Nutrients; 2018 Jul; 10(7):. PubMed ID: 30011853
[TBL] [Abstract][Full Text] [Related]
25. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
Li L; Sapkota M; Gao M; Choi H; Soh Y
Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
[TBL] [Abstract][Full Text] [Related]
26. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
[TBL] [Abstract][Full Text] [Related]
27. Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.
Han SY; Kim YK
Am J Chin Med; 2019; 47(2):439-455. PubMed ID: 30827151
[TBL] [Abstract][Full Text] [Related]
28. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
29. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
30. Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway.
Li Y; Zhuang Q; Tao L; Zheng K; Chen S; Yang Y; Feng C; Wang Z; Shi H; Shi J; Fang Y; Xiao L; Geng D; Wang Z
Cell Prolif; 2022 Oct; 55(10):e13291. PubMed ID: 35708050
[TBL] [Abstract][Full Text] [Related]
31. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
[TBL] [Abstract][Full Text] [Related]
32. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
[TBL] [Abstract][Full Text] [Related]
33. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
[TBL] [Abstract][Full Text] [Related]
34. Oleanolic acid inhibits RANKL-induced osteoclastogenesis via ER alpha/miR-503/RANK signaling pathway in RAW264.7 cells.
Xie BP; Shi LY; Li JP; Zeng Y; Liu W; Tang SY; Jia LJ; Zhang J; Gan GX
Biomed Pharmacother; 2019 Sep; 117():109045. PubMed ID: 31176167
[TBL] [Abstract][Full Text] [Related]
35. Water extract of Cnidii Rhizoma suppresses RANKL-induced osteoclastogenesis in RAW 264.7 cell by inhibiting NFATc1/c-Fos signaling and prevents ovariectomized bone loss in SD-rat.
Lee KY; Kim JH; Kim EY; Yeom M; Jung HS; Sohn Y
BMC Complement Altern Med; 2019 Aug; 19(1):207. PubMed ID: 31399090
[TBL] [Abstract][Full Text] [Related]
36. Rubiadin-1-methyl ether from Morinda officinalis How. Inhibits osteoclastogenesis through blocking RANKL-induced NF-κB pathway.
He YQ; Zhang Q; Shen Y; Han T; Zhang QL; Zhang JH; Lin B; Song HT; Hsu HY; Qin LP; Xin HL; Zhang QY
Biochem Biophys Res Commun; 2018 Dec; 506(4):927-931. PubMed ID: 30392907
[TBL] [Abstract][Full Text] [Related]
37. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
[TBL] [Abstract][Full Text] [Related]
38. Taxifolin Inhibits Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis of Human Bone Marrow-Derived Macrophages in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo.
Zhang HQ; Wang YJ; Yang GT; Gao QL; Tang MX
Pharmacology; 2019; 103(1-2):101-109. PubMed ID: 30522105
[TBL] [Abstract][Full Text] [Related]
39. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
40. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
